Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Phio Pharmaceuticals Corp.PHIO · Entity 7889 | VP, CFO | September 11, 2024 | September 13, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Phio Pharmaceuticals Corp.
Report date September 11, 2024 · Filed September 13, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 Par ValueSEC Table I · non-derivative | Direct | 11,000 |
Reported balance
After 2024-09-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-09-11 · Grant · Acquired 3,000 · Balance 11,000 F1: Represents shares underlying a restricted stock unit, which shares will vest in one year on the first anniversary. F2: Includes shares of common stock underlying unvested restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares underlying a restricted stock unit, which shares will vest in one year on the first anniversary.
F2: Includes shares of common stock underlying unvested restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 11, 2024 Filed Sep 13, 2024 15:00 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon Stock, $0.0001 Par Value | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-24-006377 · ownership.xml · nonDerivative · entry 1 Infarinato Robert M. · CIK 0002032518 · VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one year on the first anniversary. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| August 13, 2024 Filed Aug 15, 2024 16:14 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock, $0.0001 par value | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-24-005773 · ownership.xml · nonDerivative · entry 1 Infarinato Robert M. · CIK 0002032518 · VP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in three equal annual installments commencing on the first anniversary of the grant date. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.